Additionally, according to Wang's findings (2016), which indicated dysregulation of miR-146a contributed in tau hyperphosphorylation and AD pathogenesis63, we suggest that inhibition of this microRNA by QC treatment could be an in vivo novel therapy for cognitive disorders. This evidence concerns the gene MAPT and Cognitive impairment.